Under normal circumstances, HBV replication is not cytopathic. Premature stop codons in the HBV surface protein can be selected and enriched during nucleos(t)ide analogue therapy. Replication of these variants can be cytopathic to the cell and promote apoptosis. Inadequate antiviral therapy may actually promote disease progression.